Overview

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Butylscopolammonium Bromide
Physostigmine
Salicylates
Scopolamine